Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.

ABSTRACT:

Importance

O6-methylguanine-DNA methyltransferase (MGMT [OMIM 156569]) promoter methylation (mMGMT) is predictive of response to alkylating chemotherapy for glioblastomas and is routinely used to guide treatment decisions. However, the utility of MGMT promoter status for low-grade and anaplastic gliomas remains unclear due to molecular heterogeneity and the lack of sufficiently large data sets.

Objective

To evaluate the association of mMGMT for low-grade and anaplastic gliomas with chemotherapy response.

Design, setting, and participants

This cohort study aggregated grade II and III primary glioma data from 3 prospective cohort studies with patient data collected from August 13, 1995, to August 3, 2022, comprising 411 patients: MSK-IMPACT, EORTC (European Organization

SUBMITTER: Kinslow CJ 

PROVIDER: S-EPMC10196932 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature